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The activation of the proteolytic plasminogen activ-
ator system is important for the re-epithelialization
of skin wounds. Keratinocytes synthesize and secrete
the urokinase-type plasminogen activator, which
binds to its speci®c receptor on keratinocytes.
Receptor-bound urokinase-type plasminogen activ-
ator ef®ciently activates cell surface bound plasmino-
gen. This results in pericellular proteolysis, which
facilitates keratinocyte migration. Urokinase-type
plasminogen activator activity is speci®cally con-
trolled by plasminogen activator inhibitor-1 and -2.
As retinoids have been reported to accelerate epi-
thelialization of skin wounds in animal studies and
clinical settings, we investigated the effects of all-
trans retinoic acid on the plasminogen activator
system in human epidermal keratinocytes. As tested
in a chromogenic plasminogen activation assay,
incubation with 10 mM all-trans retinoic acid caused a
marked induction of cell-associated plasminogen
activity after 24 h, and this induction was blocked by
neutralizing anti-urokinase-type plasminogen activ-
ator antibodies, but not anti-tissue-type plasminogen
activator antibodies. All-trans retinoic acid lead to a
strong increase in urokinase-type plasminogen activ-
ator (enzyme-linked immunosorbent assay) and uro-
kinase-type plasminogen activator receptor cell
surface expression (¯ow cytometry) after 24 h. At
this time-point, tissue-type plasminogen activator
and plasminogen activator inhibitor-1 and -2
proteins were not or only slightly increased.
Northern blot analyses revealed that all-trans retinoic
acid caused an early and short-lived increase of plas-
minogen activator inhibitor-1, but a prolonged
induction of urokinase-type plasminogen activator
and urokinase-type plasminogen activator receptor
mRNA levels. Collectively, these data suggest that
all-trans retinoic acid activates the plasminogen activ-
ator system in human epidermal keratinocytes by
differentially regulating activating and inhibiting
components. The activation of the plasminogen
activator system may be one mechanism by which
all-trans retinoic acid exerts bene®cial effects in cuta-
neous wound healing. Key words: epithelialization/kera-
tinocyte/plasminogen activator system/retinoic acid/wound
healing. J Invest Dermatol 116:778±784, 2001
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eratinocytes synthesize and secrete the urokinase-type
plasminogen activator (uPA), which binds to its
speci®c receptor (uPAR) on keratinocytes (Kramer
et al, 1995). Receptor-bound uPA effectively acti-
vates cell surface-associated plasminogen, which in
turn cleaves various extracellular matrix components providing
pericellular proteolysis. Keratinocytes may also produce tissue-type
plasminogen activator (tPA), for which no cell surface receptor is
known. UPA and tPA activity is controlled by the speci®c
plasminogen activator inhibitor (PAI) proteins PAI-1 and PAI-2.
Activation of the PA system plays a central part for extracellular
matrix degradation under various physiologic and pathologic
conditions, including cancer invasion and cutaneous wound
healing (Kramer et al, 1995; Schmitt et al, 1995; Blasi, 1997).
Cutaneous wound healing is a complex and well-ordered process
that starts with rapid provisional wound closure by a blood clot and
leads to the reconstruction of a coherent dermal and epidermal
layer (Clark, 1999). Re-epithelialization is achieved by keratino-
cytes that migrate from wound edges or hair follicles into the
wound and later proliferate and differentiate in order to form
regular epidermis. Both migration and proliferation of keratino-
cytes are fostered by various biologic response modi®ers produced
at the wound site, including epidermal growth factor, keratinocyte
growth factor, or transforming growth factor-b. These factors
initially originate from activated platelets of the blood clot and are
later provided by in®ltrating leukocytes and ®broblasts (Martin,
1997). Keratinocytes migrate on a provisional dermal matrix and
underneath the blood clot that will be shed after re-epithelializ-
ation. In order to dissect along this migration path, keratinocytes
need to express, among other things, adhesion receptors (e.g.,
integrins) for extracellular matrix components (e.g., collagen I,
vitronectin, and ®bronectin), but also proteases such as matrix
metalloproteinases or components of the PA system (Martin, 1997;
Clark, 1999).
Several lines of evidence suggest that the PA system is necessary
for re-epithelialization. Whereas in normal human and murine
epidermis uPA, uPAR, and tPA are only detectable at low basal
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levels, in human and murine skin wounds uPA, uPAR, and, to a
lesser extent, tPA are upregulated in keratinocytes of the epithelial
outgrowth (Grondahl-Hansen et al, 1988; Jensen et al, 1988; Baird
et al, 1990; Romer et al, 1994; Jensen and Lavker, 1996).
Exogenously applied uPA stimulates re-epithelialization of skin
wounds in diabetic and nondiabetic mice (Jimenez et al, 1997). In
plasminogen-de®cient mice, re-epithelialization and wound closure
are dramatically retarded (Romer et al, 1996). In uPA-de®cient
mice, although not formally evaluated, extensive nonhealing skin
ulcerations were noted at least in a small proportion of animals
(Carmeliet et al, 1994). Impaired cutaneous wound healing was also
observed in a patient with homozygous plasminogen de®ciency
(Schott et al, 1998).
Owing to their multiple effects on cutaneous biology, vitamin A
and its derivatives can affect various aspects of wound healing
(Kligman et al, 1986; Popp et al, 1995, and references therein).
Among other things retinoids may affect wound repair by
improving epithelialization. This is supported by clinical observ-
ations: pretreatment with all-trans retinoic acid (RA) improved re-
epithelialization after super®cial skin wounding due to facial
dermabrasion, chemical peeling, or electroepilation (Mandy,
1986; Anthony et al, 1991; Hevia et al, 1991).
One mechanism by which retinoids may improve epithelializ-
ation is the activation of the PA system. Treatment of keratinocyte
cultures or skin organ cultures with RA increased uPA protein and
PA activity in culture supernatants (Varani et al, 1994, 1995). In this
study, we have systematically analyzed the effects of RA on
individual components of the PA system (uPA, uPAR, tPA, PAI-1,
and PAI-2) in human epidermal keratinocytes. We show that RA
effectively activates the PA system in human epidermal keratino-
cytes by differentially regulating its activating and inhibiting
components. We suggest that the activation of the PA system
may be one mechanism by which RA exerts bene®cial effects in
cutaneous wound healing.
MATERIALS AND METHODS
Cell culture and reagents Normal human epidermal keratinocytes
were purchased from Cell Systems (St. Katharinen, Germany) and
cultured in the keratinocyte growth medium KGM-2 consisting of the
keratinocyte basal medium KBM-2 supplemented with bovine pituitary
extract, epidermal growth factor, hydrocortisone, insulin, and transferrin
(all from Cell Systems) at 37°C and 5% CO2. Cell cultures were used for
experiments at 60±80% con¯uency and after incubation for at least 16 h
with the basal medium KBM-2 alone. RA (Sigma, Deisenhofen,
Germany) was dissolved in dimethyl sulfoxide at a concentration of
10 mM, stored at ±20°C, and freshly diluted for each experiment in
culture medium. The phorbol ester phorbol-12-myristate-13-acetate
(PMA, Sigma) was added to cells as indicated.
Plasminogen activation assay Cell-associated plasminogen activation
was assessed using a chromogenic assay. Keratinocyte cultures were
grown in 96 well plates and either left untreated, incubated with PMA
or RA. Additional cell populations were incubated with RA in
combination with one of the following reagents: inhibitory monoclonal
antibodies (50 mg per ml) against human uPA or tPA (both from
American Diagnostica, Pfungstadt, Germany); the synthetic tPA inhibitor
tPAstop (1.5 mM), which according to the manufacturer (American
Diagnostica), inhibits tPA 41.5-fold more ef®ciently than uPA and 78-
fold more ef®ciently than plasmin; or the serine protease inhibitor 2r-L
(1 mM) (StuÈrzebecher et al, 1999). Subsequently, cells were washed with
phosphate-buffered saline and incubated with 100 ml 0.5 mM
plasminogen (Roche Molecular Biochemicals, Mannheim, Germany) at
37°C for 30 min. The chromogenic plasmin speci®c substrate L1450
(Bachem, Heidelberg, Germany) was added (50 ml of a 1.5-mM solution)
and incubation continued for another 20 min, a time-point up to which
the accumulation of enzymatically cleaved L1450 was in the linear range.
Subsequently, the generation of cleaved substrate was photometrically
assessed in an enzyme-linked immunosorbent assay (ELISA) reader by
normalizing the optical density (OD) at the L1450 extinction maximum
(405 nm) against the extinction at an irrelevant wavelength (614 nm).
Normalized ODs are designated OD405±614.
Fibrin degradation assay Cell-associated plasminogen activation was
also assessed using the ®brin degradation test as described previously
(Reuning et al, 1995). Brie¯y, ®brin clots were generated in 24 well
plates by incubating 200 ml of 50 mg ®brinogen per ml (Calbiochem,
Frankfurt, Germany), 50 ml of 150 mM CaCl2, and 50 ml of 10 U
thrombin per ml (Sigma) for 1 h at 37°C. Keratinocyte cultures that
either had been left untreated or incubated with RA for 24 h were
detached by incubation with Hank's buffered salt solution (Cell Systems)
containing 0.5 mM ethylenediamine tetraacetic acid (Sigma), washed,
resuspended in KGM-2 containing a ®xed concentration (2 mg per ml)
of plasminogen, and seeded on ®brin clots. After 4 h of incubation at
37°C supernatants were collected and 25 ml were analyzed for ®brin
degradation products (including D-dimer) by ELISA (Dimertest Gold
EIA kit, American Diagnostica).
ELISA Cells were grown in six-well plates and were either left
untreated or exposed to 10 mM RA for various time-points. Supernatants
were collected and cleared from debris by centrifugation. Cells were
washed with Hank's buffered salt solution, extracted with 500 ml Triton/
Tris-buffered saline (50 mM Tris pH 7.5; 150 mM NaCl; 1% TritonX-
100) for 150 min at room temperature, and harvested with a cell scraper.
Preliminary experiments had established that the detectable amounts of
uPA, uPAR, tPA, PAI-1, and PAI-2 antigens were not decreased in cell
extracts handled at room temperature compared with extracts handled at
4°C, excluding the possibility that proteolysis had a major in¯uence on
the detected levels of antigen. Extracts were cleared from cell debris by
centrifugation. Extracts and supernatants were stored at ±80°C until
analysis. Protein concentrations were determined using the BioRad
Protein Assay reagent (BioRad, Munich, Germany). uPA, uPAR, tPA,
PAI-1, and PAI-2 concentrations in cell extracts and supernatants were
determined using the ELISA kits Imubind uPA no. 894, Imubind uPAR
no. 893, Imubind tPA no. 860, Imubind PAI-1 no. 821, and Imubind
PAI-2 no. 823, respectively (American Diagnostica) as previously
described (Schmalfeldt et al, 1995).
Flow cytometry uPAR cell surface expression was assessed by an
indirect two step staining procedure and subsequent ¯uorescence-
activated cell sorter (FACS) analysis as previously described (Marschall
et al, 1999). Brie¯y, cells were detached by incubation in Hank's
buffered salt solution containing 0.5 mM ethylenediamine tetraacetic acid
at 37°C, 5% CO2 for 30 min, carefully resuspended in, and washed
with, phosphate-buffered saline containing 1% bovine serum albumin
and 0.1% NaN3. Subsequently, cells were incubated at 4°C with either
the monoclonal mouse anti-human uPAR antibody HD 13.1 (Todd
et al, 1997) or with an isotype-matched control antibody (mouse IgG1,
DAKO, Glostrup, Denmark). In a second step, cells were incubated with
a ¯uorescein isothiocyanate-coupled goat anti-mouse antibody (Dianova,
Hamburg, Germany). Subsequently, cells were analyzed in a FACScanII
¯ow cytometer using the CellQuest software (Becton Dickinson,
Heidelberg, Germany).
Assessment of cell viability As a parameter for cell viability, cell
membrane permeability was assessed after varying periods of RA
exposure by dye exclusion experiments (propidium iodide staining).
Propidium iodide staining was assessed by ¯ow cytometry as described
previously (Behrends et al, 1994). Brie¯y, 50 ng propidium iodide
(Sigma) were added to cells, FACS analysis performed for the distinction
of intact (propidium iodide negative) from dead (propidium iodide
positive) cells, and the proportions of intact and dead cells were
determined.
RNA extraction and northern blot analysis Total cellular RNA
from cells grown in 10 cm plates was isolated using the RNA-Clean Kit
(AGS, Heidelberg, Germany). RNA (10 mg of each sample) was size
fractioned by agarose/formaldehyde electrophoresis, blotted to a
positively charged nylon membrane (Roche Molecular Biochemicals),
and ®xed to the membrane via UV cross-linking. Several digoxigenin
(DIG)-labeled hybridization probes were prepared: a 1.1 kb XbaI/EcoRI
fragment of the human uPAR mRNA (Roldan et al, 1990) was
transcribed in vitro using the DIG RNA labeling kit (Roche). The
following cDNA probes were used: a 0.9 kb PstI/BamHI fragment of the
human uPA cDNA (Turkmen et al, 1997); a 1.1 kb SalI fragment of the
human PAI-1 cDNA (Turkmen et al, 1997); or a 1.2 kb BamHI/HindIII
cDNA fragment of the human PAI-2 cDNA (Muehlenweg et al, 2000).
The cDNA fragments were labeled via random hexamer extension using
the DIG-High Prime kit (Roche). As a control for loading uniformity all
blots were also hybridized with an oligodeoxynucleotide (5¢-CGC-
CCGCCGCAGCTGGGGCGATCC) complementary to the human 28S
ribosomal RNA (Gonzalez et al, 1985), which had been DIG end labeled
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with the DIG Oligonucleotide 5¢-End Labeling Set (Roche).
Hybridizations of RNA, cDNA, or oligonucleotide probes were carried
out according to the manufacturer. Hybridization signals were
quantitated using the DIG-Luminescent Detection Kit for Nucleic Acids
(Roche Molecular Biochemicals) and subsequent exposure of Hyper®lm
ECL (Amersham, Braunschweig, Germany). Speci®c signals on ®lms
were densitometrically quantitated using the GelDoc system and software
(BioRad). Signals generated by the mRNA-speci®c hybridization probes
were normalized to the respective 28S rRNA signals. Different exposure
times were used to ensure that the signal strength of the analyzed bands
on the autoradiographs was in the linear range.
RESULTS
RA upregulates plasminogen activation in cultured
keratinocytes RA may affect the PA system by regulating
both its activating and its inhibiting components. In order to assess
the overall effect of RA on the activity of the PA system in cultured
keratinocytes, a plasminogen activation assay was performed after
exposure of cells to RA. RA was used at 10 mM, a concentration
that has previously been shown to have profound effects in
cutaneous cell types (Varani et al, 1989; Gille et al, 1997) and in our
hands did not affect cell viability for up to 48 h (data not shown).
RA increased plasminogen activation compared with untreated
controls. A slight increase was noticeable after 4 h of exposure to
RA. Induction values were maximal after 16±30 h and declined
again thereafter (data not shown). The induction was further
characterized at a time-point of maximal induction (24 h, Fig 1a).
Untreated cells showed a mean plasmin activity of 0.134 6 0.029
OD405±614. The activity of cells treated with RA, however, was
increased to 0.222 6 0.042 OD405±614. A similar induction
(0.227 6 0.083 OD405±614) was observed after a 4.5 h incubation
with 100 ng per ml PMA, which served as a positive control. The
synthetic serine protease inhibitor 2r-L markedly inhibited RA-
mediated upregulation (Fig 1b). A uPA-neutralizing antibody
blocked cell-associated plasminogen activity by 95% (Fig 1b)
implicating that both the basal and the RA-upregulated
plasminogen activation are predominantly mediated by uPA.
Consistently, a tPA-neutralizing antibody and the tPA-selective
synthetic inhibitor tPAstop failed to in¯uence the RA-induced
plasminogen activation signi®cantly.
RA upregulation of plasminogen activation in keratinocytes was
also assessed by the ®brin degradation assay. The amount of ®brin
degradation products was induced 3.33 6 1.4-fold (mean 6 SEM;
data obtained in triplicates in three independent experiments) in
cells exposed to RA for 24 h compared with untreated cells (data
not shown).
RA induces uPA and uPAR protein expression In order to
investigate how RA affects individual components of the PA
system in keratinocytes, the concentrations of uPA, uPAR, tPA,
PAI-1, and PAI-2 proteins were determined in protein extracts and
supernatants after various incubation periods with 10 mM RA. All
components of the PA system were present in extracts of untreated
keratinocytes (Table I), and the amount of PAI-2 was markedly
higher than those of the other components con®rming previous
observations (Jensen et al, 1995). Similar amounts of uPA and PAI-
1 were detected in supernatants and cell extracts, whereas uPAR,
tPA, and PAI-2 were detected in supernatants in much smaller
amounts than in cell extracts (Table I). RA induced cell-associated
uPA and uPAR in a similar time pattern with discernible
inductions after 4 h of RA, maximal induction levels between 16
and 32 h of RA incubation and declining, but still elevated levels
after 48 h of RA exposure (data not shown). Cell-associated tPA
was maximally induced after 8 h of exposure to RA (approximately
2±3-fold, data not shown) and had declined to slightly above
prestimulation values after 24 h of exposure to RA. Cell-associated
PAI-1 also displayed a short-lived induction (up to 3-fold) in
response to RA peaking after 8 h to 16 h of exposure to RA (data
not shown). There was a slight increase of cell-associated PAI-2
discernible after 16 h to 24 h of RA incubation, and PAI-2 levels
had declined again to prestimulation levels at 48 h (data not
shown). The effects of RA on uPA, uPAR, tPA, PAI-1, and PAI-2
protein levels at a time-point at which the upregulation of
plasminogen activation by RA was maximal (24 h of exposure to
RA), is illustrated in Fig 2, Table I. Cell-associated uPA and
uPAR (Fig 2a) as well as secreted uPAR (Fig 2b) were markedly
increased, whereas uPA in supernatants was only slightly elevated.
TPA and the inhibitory component PAI-1 were not increased by
RA at this time-point either in cell extracts or supernatants (Fig 2)
re¯ecting already declining levels of these molecules. There was a
slight increase in cell-associated PAI-2 and a marked increase in
secreted PAI-2 after 24 h incubation with RA, yet, even the
Figure 1. RA upregulates plasminogen activation in cultured
keratinocytes. (a) Plasminogen activation assay of cultured keratinocytes
that were either left untreated or exposed to 10 mM RA for 24 h or
100 ng PMA per ml for 4.5 h. Photometric measurements of the
plasmin-cleaved chromogenic substrate L1450 were performed as
described in Materials and Methods. Activity is depicted as mean 6 SEM
from seven (untreated controls and RA) or three (PMA) independent
experiments with quadruplicate determinations. (b) The type of PA
responsible for cell-associated RA-mediated plasminogen activation was
determined after exposure of keratinocytes for 24 h to 10 mM RA alone
or in combination with either the serine protease inhibitor 2r-L, a
monoclonal uPA-inhibitory antibody (anti-uPA), a monoclonal tPA-
inhibitory antibody (anti-tPA), or a synthetic tPA inhibitor (tPAstop).
Total PA-activity of RA-treated keratinocytes (0.210 6 0.030
OD405±614) was regarded as 100%, and the percentage of plasminogen
activity remaining after the various treatments was calculated. Values are
displayed as mean 6 SEM from four independent experiments with
quadruplicate determinations.
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increased amount of secreted PAI-2 was still minute compared with
that of the other inhibitor, PAI-1 (Table I).
When cell-surface expression of uPAR was assessed by ¯ow
cytometry, a marked increase was observed after 24 h incubation
with 10 mM RA (Fig 3), consistent with the ELISA measurements,
and was still elevated after 48 h (data not shown). Taken together,
after 24 h RA markedly increased the expression of the activating
components, uPA and its receptor uPAR in human epidermal
keratinocytes, whereas inhibiting components were not or only
slightly increased. This is consistent with the observed increased
plasminogen activation at this time-point (Fig 1).
RA increases uPA, uPAR, PAI-1, and PAI-2 mRNA
levels In order to characterize further the regulatory effects of
RA on the uPA, uPAR, PAI-1, and PAI-2 components of the PA
system, mRNA analyses were performed (Fig 4). In untreated
keratinocyte cultures basal expression of uPA, uPAR, PAI-1, and
PAI-2 mRNA was observed consistent with the detection of the
respective proteins in cell extracts and supernatants from untreated
keratinocytes. RA caused a concentration-dependent increase in
mRNA levels of all four proteins (Fig 4a). The induction was
discernible at 1 mM RA and increased with increasing RA
concentrations up to 50 mM RA with the exception of PAI-2,
which displayed ever increasing inductions up to 10 mM RA, but a
smaller induction after 50 mM RA. Time-course analysis revealed
induction of uPA, uPAR, PAI-1, and PAI-2 mRNA after as little
as 1 h incubation with RA (data not shown). Different induction
kinetics among the components of the PA system were noticed
(Fig 4b). PAI-1 induction peaked after 10±16 h exposure to RA
and then readily declined to prestimulation levels. This is consistent
with the protein measurements demonstrating early and short-lived
PAI-1 induction. UPA, uPAR, and PAI-2 mRNA were maximally
induced after 24±32 h incubation with RA. At 48 h the uPAR
mRNA level remained elevated, whereas uPA and PAI-2 mRNA
levels had markedly declined again albeit still being higher than
control levels.
Thus, the impact of RA on plasminogen activation appears to be
accompanied by distinct modulations of the mRNA levels of
individual components of the PA system.
DISCUSSION
This study documents that RA upregulates the PA system in human
epidermal keratinocytes. Importantly, it demonstrates that this is
achieved by differentially modulating activating and inhibiting
components. In other tissues, retinoids have also been found to
preferentially induce the activating components of the PA system
while leaving inhibitory factors unchanged, e.g., in human
umbilical endothelial cells (Thompson et al, 1991) or hepatic
stellate cells (Leyland et al, 1996).
Whereas it was previously noted that RA incubation of
keratinocytes augments plasminogen activity in culture supernatants
(Varani et al, 1995), this study demonstrates the upregulation of
cell-associated plasminogen activation by RA, which is important
with regard to the pericellular ®brinolysis required during wound
healing. In cultured keratinocytes we (Fig 1a) and others (Varani
et al, 1995) observed a basal plasminogen activation. In the
keratinocyte cell line HaCaT, this basal plasminogen activation is
mainly due to uPA, but not tPA, activity (Reinartz et al, 1996). In
accordance with this, the cell-associated RA-upregulated plasmi-
nogen activation observed in this study was due to uPA rather than
tPA activity (Fig 1b). Although an early induction of tPA protein
expression by RA was observed, at a time-point of maximal RA
upregulation of plasminogen activation (after 24 h incubation), RA
caused a marked induction of only uPA, but not tPA, protein
expression in human cultured keratinocytes (Fig 2). This con®rms
a previous observation at a later time-point (after 48 h incubation
with RA), when only increased amounts of uPA, but not tPA,
were detected in supernatants (Varani et al, 1995). In murine
keratinocytes, however, induction of tPA by RA has been observed
(Brown et al, 1992). The relevance of our observations in
keratinocyte monocultures for wound healing is supported by
immunohistologic data both in murine and human wounds, which
suggest that uPA is the predominant PA in the epithelial
outgrowth, whereas very little (mouse) or no (human) immuno-
reactive tPA is detected (Grondahl-Hansen et al, 1988).
Figure 2. RA induces uPA and uPAR protein expression in
cultured human epidermal keratinocytes. Concentrations of
components of the PA system in cell extracts and supernatants were
measured by ELISA as described in Materials and Methods. Induction of
protein expression in cell extracts (a) and supernatants (b) of cells exposed
to 10 mM RA for 24 h compared with untreated controls is depicted as
mean 6 SEM from three independent experiments with duplicate
determinations.
Table I. RA differentially modulates uPA, uPAR, tPA,
PAI-I, and PAI-2 expression in cultured keratinocytesa
uPA uPAR tPA PAI-1 PAI-2
Cell associatedb
Untreated 28 6 4 4 6 l 15 6 6 62 6 10 4424 6 1592
RAc 216 6 23 17 6 3 20 6 5 70 6 7 7198 6 2929
Supernatant
Untreated 72 6 27 0.04 6 0.02 6 6 l 104 6 28 0.4 6 0.1
RAc 98 6 19 0.20 6 0.13 6 6 1 105 6 27 2 6 1
aConcentrations of components of the PA system in cell extracts and super-
natants were measured by ELISA as described in Materials and Methods. Values are
expressed as ng per mg protein (cell extracts) or ng per ml (supernatants) and
represent mean 6 SEM (three independent experiments with duplicate determina-
tions).
bFor a direct comparison of protein amounts in extracts and supernatants, cell-
associated values are multiplied by a factor of 2.5 (approximately 0.4 mg extracted
protein per well) and values for supernatants by a factor of 1.0 (1 ml supernatant
per well).
cMeasurements after exposure to 10 mM RA for 24 h.
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Furthermore, disturbances of wound healing were observed at least
in a small proportion of transgenic mice de®cient in uPA
(Carmeliet et al, 1994), but not in transgenic mice de®cient in
tPA (Bugge et al, 1996). Taken together, our data further support
the view that RA-upregulated plasminogen activation is primarily
due to modulation of uPA, but not tPA, expression. It seems,
however, possible that, if RA is applied to skin around the time of
wounding, RA-induced tPA from other sources, e.g., from dermal
®broblasts (Varani et al, 1995) may contribute to plasminogen
activation at the epithelial outgrowth.
Figure 3. RA induces uPAR cell surface
expression in cultured human epidermal
keratinocytes. FACS analysis of untreated
controls or cells exposed to 10 mM RA for 24 h.
Staining was performed with either an anti-uPAR
monoclonal antibody (solid lines) or an isotype
control monoclonal antibody (dotted lines). One
representative of three independent experiments is
displayed.
Figure 4. RA increases uPA, uPAR, PAI-1, and PAI-2 mRNA levels in cultured human epidermal keratinocytes. Northern blot analysis
was performed as described in Materials and Methods with total cellular RNA isolated from cultured keratinocytes that were either left untreated or
stimulated with RA or PMA. Blots (left panels) and densitometric quantitations of speci®c signals (right panels) are displayed. 28S, hybridization with a
28S rRNA oligodeoxynucleotide as a control for loading uniformity. (a) Effect of different concentrations of RA (1±50 mM, 10 h incubation) or
100 ng per ml PMA (4 h incubation). The data are from one of three independent experiments with similar results. (b) Time course of RA stimulation
(10 mM RA). The data are representative of three (10 h and 24 h time-points) or two (16 h, 36 h, and 48 h time-points) experiments with similar
results.
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PAI-2 was detected at much higher levels than the other
components of the PA system, but only a very small proportion
appeared to be secreted. This is in accordance with a previous
observation (Jensen et al, 1995). Although extracellular PAI-2 has
been demonstrated to form complexes with secreted uPA in
keratinocytes (Reinartz et al, 1996), the vast majority of PAI-2 is
retained within the cell (Jensen et al, 1995; Risse et al, 2000) and
has no inhibitory effect on extracellular plasminogen activation.
Intracellular PAI-2 is induced in keratinocytes by an increase of the
calcium concentration in the culture medium (Jensen et al, 1995),
and PAI-2 mRNA and antigen is preferentially detected in
suprabasal epidermal layers (Lyons-Giordano et al, 1994), suggest-
ing an intracellular function in keratinocyte terminal differentiation.
The induction of PAI-2 by RA may, therefore, be interpreted as an
RA-related differentiation signal.
It has been consistently observed both in animal models (Hung
et al, 1989) and clinical settings (Mandy, 1986; Anthony et al, 1991;
Hevia et al, 1991) that treatment of the skin with retinoids prior to
wounding improves re-epithelialization. In the light of our data,
one possible explanation for this phenomenon is that, due to RA
pretreatment, plasminogen activation may already be upregulated at
the time of wounding and thus accelerate the initiation of
keratinocyte migration, whereas in the physiologic course of
wound healing, upregulation of plasminogen activation occurs only
after a lag phase during which platelets, leukocytes, or ®broblasts at
the wound site begin to deliver growth factors and cytokines that
upregulate plasminogen activation in keratinocytes (Martin, 1997).
Whereas treatment of the skin with retinoids prior to wounding
accelerates epithelialization, continued topical or systemic applic-
ation of retinoids after wounding has been found to retard wound
closure in animal models (Arboleda and Cruz, 1989; Hung et al,
1989; Watcher and Wheeland, 1989). Furthermore, impaired
wound healing has been observed following laser treatment or
dermabrasion in patients taking systemic isotretinoin (Rubenstein
et al, 1985; Zachariae, 1988). The reasons for such divergent effects
are unclear at present. Possibly, in the course of wound healing the
enhancement of plasminogen activation by retinoids may become
less important due to the presence and strong action of several
physiologic enhancers of plasminogen activation, e.g., keratinocyte
growth factor (Tsuboi et al, 1993). It is also important to appreciate
that, apart from plasminogen activation, several other aspects of
epithelialization are susceptible to retinoid regulation and may thus
affect epithelialization. First, transcriptional repression of matrix
metalloproteinases, e.g., interstitial collagenase (matrix metallo-
proteinase-1) by RA has been documented (Schroen and
Brinckerhoff, 1996). Secondly, RA has profound effects on
keratinocyte integrin expression (Hakkinen et al, 1998) and may,
therefore, modulate the integrin pattern during wound healing
(Hertle et al, 1992; Larjava et al, 1993). Thirdly, RA may affect
keratinocyte proliferation. In keratinocytes that are growth-
suppressed due to culture in growth factor de®cient medium,
RA initiates proliferation suggesting that RA may in vivo stimulate
quiescent epidermal keratinocytes (Varani et al, 1989) and thus
accelerate keratinocyte proliferation at around the time of wound-
ing. On the other hand, keratinocyte proliferation stimulated by
keratinocyte growth factor, which is important in later stages of
wound healing, is inhibited by concomitant RA treatment (Varani
et al, 1989), an observation that may help explain the inhibition of
wound healing observed when RA treatment is continued during
wound healing.
Retinoids are thought to exert their cellular effects by interaction
with intracellular RA receptors (RAR). The RAR form hetero-
dimers with retinoic X receptors (RXR); there are several different
RAR (a, b, and g) and RXR (a, b, and g) (Kang and Voorhees,
1999). Upon binding of RA, the RAR/RXR complexes act as
transcription factors either directly by binding to RA response
elements (RARE) or indirectly via interaction with other
transcription factors, e.g., AP-1 (transcriptional cross-talk) (Pfahl,
1993). The details of the transcriptional effects of retinoids within
the PA system have been partially revealed. The human uPA
promoter lacks a canonical RARE, but can be activated via
transcriptional cross-talk with SP-1 by complexes consisting of RA
and RAR/RXR receptors (Suzuki et al, 1999). Thus, it may be
assumed that transcriptional cross-talk with SP-1 contributes to the
observed RA induction of uPA in cultured keratinocytes. In the
mouse uPA promoter, transcriptional cross-talk with a different
DNA binding factor, AP1, has been reported (Mira-Y-Lopez et al,
1998). The tPA and PAI-2 genes both possess RARE that are
functionally active within certain cell types (Bachmann, 1995;
Bulens et al, 1995), and these elements may be involved in the
observed tPA and PAI-2 inductions in cultured keratinocytes. The
molecular mechanisms by which retinoids modulate PAI-1 and
uPAR expression remain to be elucidated.
In conclusion, the data suggest that RA activates the PA system
in human epidermal keratinocytes by differentially regulating
activating and inhibiting components. The activation of the PA
system may be one mechanism by which RA exerts bene®cial
effects in cutaneous wound healing.
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